The AVA Emulation System is our groundbreaking “Ad Vivo Architect,” bridging the translation gap by merging the throughput of in vitro studies with the fidelity of in vivo models to create more human-relevant biology at scale.
By supporting up to 96 individual Organ-Chip samples (“Emulations”) per experiment, AVA delivers high-powered insights that enable faster, more confident decision-making in drug development.
Read on to learn more about the system and how its transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory.
Mack Degueurin 22 April 2025 The wearable device analyzes the tiny changes in physical responses…
Emily N. Reinke, Joe Reynolds, Nicola Gilmour, Georgia Reynolds, Judy Strickland, Dori Germolec, David G.…
Beatrice Wihlander 7 May 2025 A study from Stanford University, US, has found that beauty…